STA
NVCR icon

Summit Trail Advisors’s NovoCure NVCR Stock Holding History

Summit Trail Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.5M Sell
98,814
-5,181
-5% -$78.4K 0.02% 793
2026
Q1 		$1.13M Buy
103,995
+18,731
+22% +$234K 0.02% 877
2025
Q4 		$1.1M Sell
85,264
-3,049
-3% -$39.1K 0.02% 763
2025
Q3 		$1.14M Buy
88,313
+17,916
+25% +$239K 0.02% 755
2025
Q2 		$1.25M Buy
70,397
+14,799
+27% +$258K 0.02% 392
2025
Q1 		$991K Buy
55,598
+40,570
+270% +$921K 0.03% 160
2024
Q4 		$448K Sell
15,028
-4,089
-21% -$86.5K 0.02% 235
2024
Q3 		$299K Buy
+19,117
New +$347K 0.01% 549

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Summit Trail Advisors's NVCR Position: Q2 2026 in Review

Summit Trail Advisors reduced its NovoCure (NVCR) stake by 5% in Q2 2026, selling an estimated $78.4K and leaving 98,814 shares worth $1.5M. The position accounts for 0.02% of the portfolio, ranked #793.

Summit Trail Advisors first reported a position in NVCR in Q3 2024 and has held it in 8 quarters since. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Summit Trail Advisors held 98,814 shares of NovoCure worth $1.5M as of Q2 2026.
  • Summit Trail Advisors sold 5,181 NovoCure shares in Q2 2026, an estimated $78.4K.
  • NovoCure made up 0.02% of Summit Trail Advisors's portfolio in Q2 2026, its #793 holding.
  • Summit Trail Advisors first reported a position in NovoCure in Q3 2024 and has held it in 8 quarters since.
  • 218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.